Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B
Open Access
- 15 May 2013
- journal article
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 7 (3) , 329-334
Abstract
Kim DY, et al. Gut Liver. 2013 May;7(3):329-334. http://dx.doi.org/10.5009/gnl.2013.7.3.329Keywords
This publication has 23 references indexed in Scilit:
- EASL Clinical Practice Guidelines: Management of chronic hepatitis BJournal of Hepatology, 2009
- Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced DiseaseAntiviral Therapy, 2007
- Hepatitis B virus genetic diversity and its impact on diagnostic assaysJournal of Viral Hepatitis, 2007
- Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2006
- A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2006
- Durability of Serologic Response After Lamivudine Treatment of Chronic Hepatitis BHepatology, 2003
- In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistanceHepatology, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Analysis of Hepatitis B Virus Quasispecies Changes during Emergence and Reversion of Lamivudine Resistance in Liver TransplantationAntiviral Therapy, 1999
- A One-Year Trial of Lamivudine for Chronic Hepatitis BNew England Journal of Medicine, 1998